<DOC>
	<DOCNO>NCT00896376</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient cancer may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This clinical trial study side effect trastuzumab treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Trastuzumab Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate predictive value genetic factor toxicity efficacy trastuzumab-based therapy woman metastatic breast cancer . Secondary - To analyze tumor factor potentially related efficacy trastuzumab ( i.e. , expression protein involve cell proliferation survival ) . OUTLINE : This multicenter study . Patients receive standard treatment trastuzumab . Blood collect periodically pharmacogenetic analysis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Metastatic disease , define existence secondary tumor localization radiologically ( i.e. , radiography , CT scan , MRI scan , ultrasound ) scintigraphically confrimed Evaluable disease Beginning firstline metastatic treatment trastuzumab ( HerceptinÂ® ) without chemotherapy Primary tumor must overexpress HER2 ( IHC 3+ OR IHC 2+ FISH+ OR FISH+ ) Hormone receptor status specify No brain metastasis PATIENT CHARACTERISTICS : Menopausal status specify Life expectancy &gt; 3 month Able undergo cardiotoxicity evaluation every 4 month measure LVEF via isotopic method ultrasound systematic registration No chronic uncontrolled disease No heart failure No respiratory failure hypoxemia No history another primary cancer except basal cell carcinoma skin No severe uncontrolled infection No psychological incapacity PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>